Doximity (NYSE:DOCS) Director Kira Scherer Wampler Sells 2,000 Shares of Stock

Doximity, Inc. (NYSE:DOCS) Director Kira Wampler sold 2,000 shares of Doximity stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $32.89, for a total transaction of $65,780.00. Following the sale, the director directly owned 27,923 shares in the company, valued at approximately $918,387.47. The trade was a 6.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kira Scherer Wampler also recently made the following trade(s):

• On Thursday, October 1st, Kira Wampler sold 2,000 shares of Doximity stock. The shares were sold at an average price of $28.91, for a total value of $57,820.00.
• On Tuesday, August 25th, Kira Wampler sold 2,000 shares of Doximity stock. The stock was sold at an average price of $24.95, for a total value of $49,900.00.

Doximity Stock Performance

Shares of Doximity stock opened at $34.64 on Thursday. The stock has a 50 day moving average of $28.78 and a 200 day moving average of $25.59. The firm has a market capitalization of $6.17 billion, a price-to-earnings ratio of 40.75, a PEG ratio of 25.50 and a beta of 1.29. Doximity, Inc. has a fifty-two week low of $17.15 and a fifty-two week high of $66.11.

Doximity (NYSE:DOCS) last posted its earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.13. Doximity had a return on equity of 18.06% and a net margin of 25.48%. The company had revenue of $156.62 million for the quarter. During the same quarter in the prior year, the firm earned $0.36 EPS. Doximity’s revenue for the quarter was up 7.3% compared to the same quarter last year. Analysts forecast that Doximity, Inc. will post 0.74 EPS for the current year.

Key Headlines Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Valuation commentary points to potential upside: one article says a model sees about 53% upside, and another describes Doximity as roughly 3% undervalued following its DoseCheck and UpToDate rollout. These are model-based assessments, not guarantees or new company guidance. Earnings To Watch: Doximity Inc (DOCS) Q2 2027 — GF Value Sees 53% Upside Doximity Could Be 3% Undervalued Following DoseCheck And UpToDate Rollout
• Neutral Sentiment: Investors are looking ahead to Doximity’s fiscal Q2 2027 results for the quarter ended September 2026. The articles preview Wall Street estimates and key metrics but do not report results, so they provide no confirmed earnings surprise. Q2 Performance and Wall Street Estimates
• Negative Sentiment: Several law firms are publicizing a pending securities class action and a November 16, 2026 lead-plaintiff deadline. The complaint alleges Doximity overstated the Newsfeed product’s contribution to revenue growth and its competitive position; these are allegations, not established findings. Litigation can add uncertainty and reputational risk. DOCS Securities Class Action Deadline Alert

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on DOCS shares. JPMorgan Chase & Co. raised their price objective on Doximity from $26.00 to $31.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $27.00 target price on shares of Doximity in a research note on Tuesday, September 8th. Truist Financial increased their target price on shares of Doximity from $19.00 to $24.00 and gave the stock a “hold” rating in a research note on Thursday, August 13th. Piper Sandler reiterated an “overweight” rating and set a $47.00 price target (up from $42.00) on shares of Doximity in a research report on Friday, August 7th. Finally, Evercore set a $35.00 price target on shares of Doximity in a research note on Tuesday, September 29th. Eight research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $30.73.

Institutional Trading of Doximity

Several hedge funds have recently made changes to their positions in DOCS. Signaturefd LLC boosted its holdings in Doximity by 10.4% in the third quarter. Signaturefd LLC now owns 4,205 shares of the company’s stock valued at $119,000 after purchasing an additional 397 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Doximity by 59.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock valued at $53,000 after purchasing an additional 695 shares in the last quarter. Apella Capital LLC lifted its holdings in Doximity by 1.4% during the 3rd quarter. Apella Capital LLC now owns 59,488 shares of the company’s stock worth $1,647,000 after buying an additional 802 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Doximity by 19.8% in the third quarter. GAMMA Investing LLC now owns 5,834 shares of the company’s stock valued at $165,000 after purchasing an additional 963 shares in the last quarter. Finally, Leonteq Securities AG lifted its position in shares of Doximity by 65.6% during the 1st quarter. Leonteq Securities AG now owns 2,912 shares of the company’s stock worth $68,000 after buying an additional 1,154 shares during the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.

About Doximity

Doximity, Inc operates a digital platform designed for medical professionals in the United States. Its network connects physicians, nurse practitioners, physician assistants, pharmacists and other healthcare professionals, providing tools for professional communication, collaboration and career development.

The company offers services including secure messaging, telehealth, digital faxing, physician scheduling and professional networking. Doximity also provides medical news and educational content, as well as recruiting and job-search resources for healthcare professionals.

Doximity generates additional revenue through digital marketing and engagement solutions for pharmaceutical companies, healthcare organizations and health systems.